Why did PHASQ stock drop nearly 99% on 05 Mar 2026?

PHASQ stock fell about 99.00% due to thin liquidity, a potential delisting notice and lingering Chapter 11 restructuring effects, which drove selling pressure and pushed the public quote near zero.

What is Meyka AI’s grade for PHASQ stock and what does it mean?

Meyka AI rates PHASQ at **62.99 / 100 (Grade B)** with a HOLD suggestion. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus.

Does PhaseBio (PHASQ) have meaningful assets that could lift the stock?

PhaseBio has clinical assets such as bentracimab (PB2452) in Phase III and other cardiopulmonary candidates; positive clinical or licensing news would be the primary path to lifting PHASQ stock.

What is the Meyka AI forecast for PHASQ stock and should I trade it?

Meyka AI's forecast model projects **$0.00** under the baseline scenario. Forecasts are model-based projections and not guarantees; trading PHASQ stock carries high liquidity and regulatory risk.

US Stocks

PHASQ PhaseBio Pharmaceuticals, Inc. (PNK) down 99% 05 Mar 2026: key risks ahead

ByDanny Kontos March 6, 2026March 6, 2026

PHASQ stock plunged about 99.00% to $0.00 on 05 Mar 2026 during U.S. market hours on the PNK exchange, with 2,500 shares reported for the session. The steep drop follows continued illiquidity, a previous Chapter 11 filing and a notice that the company may be delisted, which pushed the quote near zero. Investors should note the stock’s 52-week high was $0.04 and the company still shows negative earnings with EPS -2.14. This report explains what moved the PHASQ stock price and offers an analyst view on the outlook.